TABLE 5.
Summary of anti-drug antibody after a single-dose intravenous infusion of etesevimab
| Etesevimab |
Placebo (n = 10) | Overall (n = 40) | |||||
|---|---|---|---|---|---|---|---|
| 2.5 mg/kg (n = 4) | 10 mg/kg (n = 12) | 25 mg/kg (n = 12) | 50 mg/kg (n = 12) | Combined (n = 30) | |||
| ADA test post dose | |||||||
| Negative | 2 (66.7%) | 9 (100%) | 8 (88.9%) | 9 (100%) | 28 (93.3%) | 9 (90.0%) | 37 (92.5%) |
| Positive | 1 (33.3%) | 0 | 1 (11.1%) | 0 | 2 (6.7%) | 1 (10.0%) | 3 (7.5%) |
| Time from randomization to initial ADA positive | |||||||
| Subject no. | 1 | 0 | 1 | 0 | 2 | 1 | 3 |
| Median (min, max) | 14 (14, 14) | 29 (29, 29) | 21.5 (14, 29) | 15 (15, 15) | 15 (14, 29) | ||